New Approach to Regenerative Medicine

Leveraging its proprietary non-invasive technology, SANUWAVE is well positioned to garner a share of multiple regenerative medicine market segments totaling $10 billion.
The Company has already completed a pivotal Phase III Investigational Device Exemption (IDE) clinical trial for the treatment of diabetic foot ulcers for its dermaPACE® device. The trial was very favorable, demonstrating statistically and clinically significant results. The dermaPACE® device to treat diabetic foot ulcers could be approved sometime in 1H12